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Objectives: Abiraterone acetate and enzalutamide, novel anti-androgen therapies 
with distinct modes of action for the treatment of metastatic castration-resistant 
prostate cancer (mCRPC), are approved in both the pre-chemotherapy and post-
chemotherapy settings. These anti-androgen therapies have significantly improved 
outcomes among mCRPC patients. However, to date there is little published evidence 
regarding patients’ real-world experience of these therapies in both the pre-chem-
otherapy or post-chemotherapy settings, particularly in terms of health-related 
quality of life (HRQoL) and treatment satisfaction. MethOds: Qualitative face-to-
face interviews were conducted with mCRPC patients (n= 38) and carers (n= 12) to 
obtain in-depth data concerning the patient experience with novel anti-androgen 
therapy. This included patients with experience of abiraterone acetate or enzalu-
tamide in either the pre-chemotherapy or post-chemotherapy setting in France, 
Germany and the UK. Findings from this study have been used to inform the design 
of a larger quantitative, multinational online survey to further explore and quantify 
HRQoL and treatment satisfaction among mCRPC patients receiving anti-androgen 
therapy. Results: Patients generally had high expectations at initiation of ther-
apy with a primary emphasis on reduction in prostate-specific antigen levels and 
improvements in HRQoL. Patients and carers reported that experiences on treat-
ment had met or exceeded expectations. Administration procedures appeared to 
be of limited concern for patients and only mentioned by patients when prompted 
by directive questions. In particular, the need to take abiraterone acetate on an 
empty stomach was not deemed problematic. Some differences in the patient 
experience (e.g. side effects) and HRQoL of patients receiving abiraterone acetate 
and enzalutamide were noted and warrant further exploration. cOnclusiOns: 
Patients and carers reported largely positive experiences with novel anti-androgen 
therapies for the treatment of mCRPC. Potential differences between regimens in 
terms of treatment satisfaction and HRQoL are currently being explored in a larger 
quantitative online study.
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Objectives: The FDA has previously noted that data reported directly by patients 
about how they are feeling and functioning (i.e. patient reported outcomes (PROs)) 
are rarely included in oncology drug labelling claims in the United States, with 
end points relating to survival, imaging and biomarkers tending to take priority. 
However, while research suggests an increase in PRO use in oncology trials, signifi-
cant challenges remain and a low burden solution for all stakeholders is becom-
ing increasingly important. MethOds: Key challenges for integrating PROs into 
oncology clinical trials were identified based on study protocols, sponsor feedback 
and best practices from previous oncology studies. Based on this feedback an elec-
tronic solution for capturing data in oncology studies was developed. Results: 
Patient and site burden were identified as key challenges in oncology studies 
deploying PROs. Oncology patients can be very impaired, so requiring the com-
pletion of lengthy questionnaires can result in non-compliance. A user focused 
electronic system reduces the burden of patients providing answers to question-
naires, and opens the possibility for data capture to occur at home rather than at 
study visits. Feedback also highlighted that sites struggle with organizing visits 
and staying protocol compliant. An electronic visit scheduling tool can help sites 
keep track of what order and at which visits questionnaires should be completed 
and to help remind and reschedule patient visits. cOnclusiOns: Obtaining a 
proper understanding of the patients experience in oncology clinical studies is 
increasingly becoming a priority for multiple stakeholders, not least the patients 
themselves. While there is evidence that the number of PROs being included in 
oncology studies is increasing over time there are still significant challenges to 
capturing high-quality PRO data. A holistic electronic solution, which considers 
both the patients and sites experience of providing data, can reduce the barriers 
to capturing high-quality PRO data.
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Objectives: Research on adherence, health outcomes and shared decision mak-
ing all highlight the importance of understanding patient treatment preferences. 
However, a recent systematic review (Shingler et al., 2014) showed how little work 
has explored treatment preferences of oncology patients. The aim of the present 
study was to identify issues from previous patient preference research in oncology 
to design a novel protocol to explore treatment preferences of men with metastatic 
prostate cancer. MethOds: It was hypothesised that the low number of reported 
studies in oncology may be due to methodological issues encountered in studies. 
A review of stated preference research completed in oncology identified different 
issues. This information was then used to design a protocol for a patient prefer-
ence study in men with metastatic castrate resistant prostate cancer. Results: 
Identified issues include (i) the use of inappropriate attributes (describing death, 
survival or progression), (ii) challenges with recruitment, sometimes associated 
symptoms, often painful and debilitating (Mughal et al. 2014). Developed from 
the widely used MPN-SAF, the 7-item MPN-SAF TSS was modified with word-
ing changes and by adding one tiredness item to better meet regulatory needs 
and assess symptom severity in myelofibrosis to support treatment benefit end-
points in clinical research. Study objectives were to translate the mMPN-SAF TSS 
into 21 languages for 26 countries and to assess comprehension and concep-
tual equivalence with the English source version in order to expand its use in 
global myelofibrosis research. MethOds: The mMPN-SAF TSS was translated 
following ISPOR guidelines for linguistic validation of PRO measures (Wild et 
al., 2005) using the universal approach (Wild et al., 2009). For each non-English 
language, two forward translations by native translators, reconciliation of for-
ward translations, back-translation by one English-speaker fluent in the target 
language, and final reconciliation by a native-speaking language coordinator 
were conducted. Harmonization (i.e., comparison between languages for con-
sistent interpretation) was performed to ensure conceptual equivalence across 
languages. Interviews were conducted with 4-5 native-speaking myelofibrosis 
patients for each language/country combination (N= 142). Interview data were 
analyzed qualitatively to assess linguistic and cultural validity in each language 
and confirm conceptual equivalence. Results: Mean age was 60 years (range 
25-88); 51% were male. The translations were well understood and considered 
relevant with some patients raising minor issues during interviews. Patient 
feedback resulted in wording changes to the Bulgarian, Czech, Danish, Dutch, 
German, Hebrew, Hungarian, Japanese, Korean, Malay, Russian, Spanish, Simplified 
and Traditional Chinese versions. cOnclusiOns: All translated versions of the 
mMPN-SAF TSS were confirmed to be conceptually equivalent and well understood 
in the 26 countries evaluated. These translations fill a significant need for patient-
focused instruments in local languages to facilitate future myelofibrosis research 
worldwide.
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Objectives: The Finnish language has no no function-related cancer-specific 
outcome measures. The authors translated the Toronto Extremity Salvage Score 
(TESS) and the Musculoskeletal Tumor Society (MSTS) into Finnish and pilot tested 
the versions. MethOds: Translation and transcultural adaptation was adhered to 
the guidelines of the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR). Lower-limb TESS and MSTS outcome measures underwent 
forward-backward translation into Finnish. A multidisciplinary panel reviewed 
the process and proposed pre-final Finnish versions. Between March and May 
2015, altogether 18 consecutive patients who had undergone limb-sparing surgery 
for lower extremity soft tissue sarcoma (STS) visited the outpatient clinic of the 
Helsinki University Hospital Department of Oncology and completed the TESS, 
while simultaneously undergoing clinical assessment with the MSTS. Participants 
were interviewed to reveal problems in the translations. Results: The transla-
tion process revealed minor cultural differences between the translations of the 
TESS, which required adjustments. The MSTS translated well. After evaluating the 
measurement outcomes, the median TESS and MSTS scores were 85.5% (range, 
51.5-100.0%) and 76.7% (range, 26.7-100.0%), respectively. In both outcome meas-
ures, the authors noted a 5% ceiling effect. cOnclusiOns: The pilot testing of the 
Finnish translation of the lower-limb TESS and MSTS indicated a good functional 
outcome in most patients who underwent lower limb-sparing surgery for STS. 
The TESS and the MSTS measurement outcomes correlated relatively closely. The 
psychometric properties of the Finnish versions of the lower-limb TESS and MSTS 
warrant further studying.
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Objectives: Receiving chemotherapy causes moderate to severe adverse events 
which deteriorate to both body and mind of breast cancer patients. Some ques-
tionnaires were developed to measure breast cancer patients’ quality of life e.g., 
the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-
C30, the Functional Assessment of Cancer Therapy for Breast cancer (FACT-B). 
Howereve, those questionnaires were rarely used in routine practice due to time 
consuming in difficulty in outcome evaluation. Therefore, we need to develop 
the practical questionnaire to evaluate impacts of chemotherapy on the overall 
health status in breast cancer patients’ view. MethOds: We develop the ques-
tionnaire focusing on the symptoms related to adverse reaction of chemotherapy 
which patients felt and correlate with activity of daily living. The questionnaire 
consisted of 16 items for patients to answer with 5 likert scale (strongly disagree 
0 to strongly agree 4). The possible highest score were 64 and the higher score was 
the more suffering from chemotherapy in patients’ perspective. Results: One 
hundred breast cancer patients were interviewed. The average interview time was 
only 5-10 minutes per patient. Average age of patients were 52.09 ±12.77 years old 
and majority of them (71%) had stage I to III breast cancer. The average score was 
23.06 + 13.27 (minimum score was 0 and maximum score was 57 out of 64). we 
found the highest score (2.32 + 1.67) that patient reported for impacts on their 
heath from chemotherapy was “I am tried easier” and the lowest score (0.56 + 1.21) 
patient reported was “it is hard to breathe”. The factors associated with total score 
of questionnaire were adverse reactions. cOnclusiOns: Our questionnaire can 
be used as a screening tool to classify patients according to severity and urgency 
for providing pharmaceutical care especially in the practice sites with limited 
manpower of clinical pharmacists.
